- Trial phase
- Not stated
- Time to market
- Not stated
- Why 4/10
- No upcoming catalyst for PRAX-110 could be identified; the drug does not appear in any public pipeline, clinical trial database, FDA catalyst list, or press release for Praxis Precision Medicines. The company's next hard catalysts are the PDUFA dates for relutrigine (Dec 27, 2026) and ulixacaltamide (Jan 29, 2027), but these are different drugs.
PRAX-110 is not a recognized pipeline asset of Praxis Precision Medicines based on available public data. Investors should monitor the company's official pipeline disclosures for any mention of this candidate. The stock's near-term value is driven by the relutrigine PDUFA on December 27, 2026 and the ulixacaltamide PDUFA on January 29, 2027.
Price Chart
Executive Summary
PRAX-110 is not a publicly documented drug candidate from Praxis Precision Medicines. Extensive web searches, SEC filings, FDA catalyst databases, clinical trial registries, and press releases failed to return any mention of PRAX-110 as a pipeline asset. The company's known pipeline includes relutrigine (PRAX-562), ulixacaltamide, elsunersen, and PRAX-628. Without any verifiable data on PRAX-110's mechanism, indication, or clinical status, no informed investment thesis can be constructed for this specific molecule.
The Two-Sided Case
Upcoming Catalysts
- No catalysts identified for PRAX-110. For the company overall: relutrigine PDUFA on December 27, 2026; ulixacaltamide PDUFA on January 29, 2027; EMERALD study topline results expected Q4 2026.
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Praxis Precision Medicines, Inc. 8-K PRAX ·Originating report